Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Rozzano – page 229

2 815 clinical trials in Rozzano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rozzano at a glance
2 815
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 815 trials in Rozzano

Open in trial search

Dementia Alzheimer's type

Not recruiting

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Hidradenitis

Not recruiting

Study on the Effects and Safety of SAR442970 for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hodgkin's disease

Not recruiting

Study of Relatlimab and Nivolumab for Children and Young Adults with Recurrent or Refractory Hodgkin and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Triple negative breast cancer

Not recruiting

Study of RO7247669 and Nab-Paclitaxel vs. Pembrolizumab and Nab-Paclitaxel for Patients with Untreated, PD-L1 Positive, Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Effectiveness of Amlitelimab for Adults with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hormone receptor positive breast cancer+1

Not recruiting

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Antipsychotics
  • Sponsor:Gilead Sciences Inc.

Gastrointestinal stromal tumour

Not recruiting

Study of Ripretinib vs Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumor with Specific KIT Exon Mutations Previously Treated with Imatinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on Efinopegdutide and Semaglutide for Adults with Non-Alcoholic Steatohepatitis (NASH) Before Cirrhosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efinopegdutide
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer

Not recruiting

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Magnetic resonance imaging+1

Not recruiting

Study Comparing Gadoquatrane with Gadoteric Acid, Gadoteridol, and Gadobutrol for MRI in Patients with Non-CNS Conditions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Primary biliary cholangitis+1

Not recruiting

Study on Long-term Safety of Linerixibat for Treating Itchy Skin in Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Linerixibat
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Rozzano

What the registry says about research in the country

01 Oncology Research

Critical investigations focusing on various cancer types including metastatic colorectal cancer, acute myeloid leukemia, and advanced breast cancer. Studies evaluate novel therapeutic combinations and targeted treatments to improve patient outcomes.

  • Gastric and Gastroesophageal Cancer Treatments
  • Breast Cancer Therapies
  • Blood Cancer Interventions

Multiple trials exploring innovative treatment approaches for both solid tumors and hematological malignancies.

02 Respiratory and Pulmonary Studies

Research initiatives examining treatments for idiopathic pulmonary fibrosis and chronic respiratory conditions. Studies focus on improving lung function and patient quality of life.

  • Pulmonary Fibrosis Management
  • Chronic Rhinosinusitis Treatment

Investigations aim to advance therapeutic options for patients with chronic respiratory conditions.

03 Autoimmune and Inflammatory Diseases

Comprehensive research into conditions like psoriatic arthritis and systemic sclerosis. Studies evaluate new biological treatments and therapeutic approaches.

  • Inflammatory Bowel Diseases
  • Skin and Joint Conditions
  • Immune System Disorders

Trials focus on developing targeted therapies for various inflammatory conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.